The Weekly Term Sheet (44)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Tax-Neutral Demerger - A case study
DISCLAIMER
This article is provided for informational and educational purposes only. It does not constitute legal, financial, tax, or investment
Fund of the Week: Curie.Bio
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the week: Elevara Medicines
Company Overview and Corporate Structure
Elevara Medicines Ltd. is a London-based clinical-stage biotechnology company focused on innovative therapies for rheumatoid
Bankrupt Biotech Royalty Auctions: Navigating Royalty Sales
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalties Unstacked: Allocating the Proceeds in Combination Therapies
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Negative Pledge Covenants in Pharmaceutical Credit Agreements
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
The Weekly Term Sheet (43)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Volatility Laundering: Smoothing Out Risk or Sweeping It Under the Rug?
A Calm Surface Hiding Choppy Seas
Imagine a portfolio that glides through market turmoil with uncanny smoothness, scarcely registering a
Fund of the week: Nvidia's NVentures
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
